Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4105262 | 0.91 | CHRNA7 (0.66) | EPHX2TSHRALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL13873498 | 0.91 | EPHX2 (0.64) | EPHX2TSHRALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL13873823 | 0.89 | EPHX2 (0.56) | EPHX2ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL12466289 | 0.89 | EPHX2 (0.61) | EPHX2TSHRALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL4105384 | 0.88 | EPHX2 (0.59) | EPHX2TSHRALDH1A1GLACHRNA7 | |
| SCHEMBL7096653 | 0.87 | EPHX2 (0.59) | EPHX2TSHRALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL13890321 | 0.87 | EPHX2 (0.59) | EPHX2TSHRALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL7092551 | 0.85 | EPHX2 (0.57) | EPHX2TSHRALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL13873499 | 0.84 | EPHX2 (0.61) | EPHX2TSHRALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL13873500 | 0.84 | EPHX2 (0.61) | EPHX2TSHRALDH1A1CHRNA7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| EP-1996545-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | Boehringer Ingelheim International GmbH (DE) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885TSHR 4350/4885ALDH1A1 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.